Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

Summary

Study QXL138AM-001 is a Phase 1a/1b study to investigate the safety, pharmacokinetics, and preliminary activity of QXL138AM in subjects with locally advanced un-resectable and/or metastatic solid tumors and multiple myeloma. The study is an open-label, multicenter, first in human study to be conducted in two major parts which are further organized into two sub-parts. Part A Dose Escalation is a modified 3+3 with the first two cohorts consisting of one subject each based on the low clinical starting dose.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Ovarian Cancer
• Pancreas Cancer
• Urothelial Carcinoma
• Renal Cell Carcinoma
• Hepatocellular Carcinoma
• Gastrointestinal Cancer
• Lung Cancer
• Prostate Cancer
• Breast Cancer

Eligibility basics and study details

Study type

Interventional

Phase

Phase 1

Ages

18 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

Nammi Therapeutics Inc

Last updated on ClinicalTrials.gov

August 27, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites